3ICK E11.Clinical investigation of medicinal products in the pediat-ric population[EB/OL].http://www.ich.org/cache/compo/276-254-1.html.2000-07-20.
4William B.Off label prescribing in children,A view from the United States[J].BMJ,2002;324:1290-1291.
5Conroy S,Choonara I,lmpicciatore P,et al.Survey of unlicensed and off-label drug use in paediatric wards in european countries[J].BMJ,2000;320:79-82.
6Nakamura H Current status ofpediatric clinical uials-special fo-cus on physician initiated clinical trials for drug approval[J].Japa-nese Journal of Pediatric Surgery,2004;36:839-845.
7EMEA.Evidence of harm from off-label or unlicensed medicines in children[EB/OL].http://www.emea europa.eu/pdfs/human/paediatrica/12632704en.pdf.2008-11-25.
8FDA.General considerations for the clinical evaluation of drugs in infants and children[EB/OL].http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Cuidances/ucm071687.pdf.1977-09-01.
9FDA.Specific requiremengts on content and format of labeling for human prescription drugs;revision of"pediatric use"subsection in the labeling;final rule,"federal register,1994;59:64240-64250.
10FDA.food and drug administration moderization act[EB/OL].ht-tp://www,fda.gov/regulatory information/legislation/federal food drug and cosmetic actfdcact/significant amendmentstothe fdcact/fdama/full textof fdama law/default,htm.1997-11-21.
